Abstract 1485P
Background
Patients (pts) diagnosed with metastatic cancer often experience a high symptom burden and diminished health-related quality of life (HRQOL), which can significantly impact their overall well-being. Physical activity (PA) has emerged as a promising intervention to alleviate symptoms and improve HRQOL in this population. This study examines the effects of a 12-week supervised remote PA program on symptom burden and health-related quality of life (HRQOL) in pts diagnosed with metastatic cancer.
Methods
This prospective study included eligible pts undergoing treatment for metastatic cancer. Initial assessments and weekly exercise guidance were provided to pts via WhatsApp. Proper home exercise techniques were demonstrated using the Vedius platform. The prescribed exercise regimen entailed 3 to 5 hours per week (4 to 6 days a week) of combined resistance and aerobic exercises. Outcome measures, including symptom burden (Edmonton Symptom Assessment System, ESAS, scale 0-90) and overall quality of life (Functional Assessment of Cancer Therapy-General, FACT-G, scale 0-108) were evaluated at baseline and after 12 weeks. Data analysis involved descriptive statistics and the linear mixed models.
Results
A total of 62 pts, with a median age of 68 years (range: 32-88), were enrolled in the study. Among the participants, 54.8% were female, 66.1% were white, and 61.3% were married, with 57.7% holding a college degree. The most prevalent cancer types included breast (24.2%), genitourinary (19.4%), lung (14.5%), and gynecological (14.5%). Over the study period, a significant improvement was observed in symptom burden (baseline mean=21.7, follow-up mean=7.8, P=0.001) and HRQOL (baseline mean=83.4, follow-up mean=95.4, P=0.001).
Conclusions
Our findings demonstrates that a 12-week supervised remote PA program has a significant positive impact on symptom burden and HRQOL in pts with metastatic cancer undergoing treatment. These findings underscore the potential benefits of incorporating PA interventions into the management of metastatic cancer, offering a promising avenue for improving patient outcomes and well-being.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1564P - Limited participation in breast cancer screening among low-SES women: A matter of engagement or of health literacy?
Presenter: Allegra Ferrari
Session: Poster session 10
1566P - Optimizing participation in lung cancer screening program: Results from the first round in ILYAD study in Lyon University Hospital
Presenter: Emmanuel Grolleau
Session: Poster session 10
1567P - Physicians' adenoma detection rate and the risk of colorectal cancer in sequential screening programs: An observational cohort study
Presenter: Li Xie
Session: Poster session 10
1568P - Challenges in pilot lung cancer screening in Vojvodina, Serbia
Presenter: Jelena Djekic Malbasa
Session: Poster session 10
1569P - Secondary delay in breast cancer diagnosis and role of rural medical practitioners: A cause and cure finding study
Presenter: Rahul Agarwal
Session: Poster session 10
1570P - Factors and impacts of delayed presentation for county-level patients with breast cancer in a real-life setting in China
Presenter: Yinghua Ji
Session: Poster session 10
1571P - The reasons that motivate a change of specialties among oncology residents
Presenter: Christophe Ducrocq
Session: Poster session 10
1572P - Factors associated with career choice in oncology among medical students
Presenter: Nicolas Penel
Session: Poster session 10
1573P - Global cancer statistics for adolescents and young adults: New estimates from GLOBOCAN 2022
Presenter: Wang-Zhong Li
Session: Poster session 10
Resources:
Abstract